Percutaneous cervical cordotomy offers significant cancer pain relief

  • Poolman M & al.
  • BMJ Support Palliat Care
  • 27 mar. 2020

  • de Kelli Whitlock Burton
  • Clinical Essentials
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Takeaway

  • Percutaneous cervical cordotomy (PCC) significantly reduces cancer pain and opioid consumption and improved QoL, with few adverse events (AEs), according to a preliminary analysis of a UK PCC patient registry.
  • Median survival after PCC was only 1.3 months, suggesting patients were referred for PCC during the later stages of disease.

Why this matters

  • Although cordotomy is usually prescribed for unilateral cancer pain in patients with

Study design

  • Analysis of 159 patients (age ≥18 years) with cancer who underwent PCC for pain treatment performed during 2012-2017.
  • Outcomes: relief of cancer pain.
  • Funding: NCRI SuPaC Lung Cancer; North Wales Awyr Las fund; others.

Key results

  • The median time from cancer diagnosis to PCC assessment was 13.3 (interquartile range, 6.2-23.2) months.
  • PCC was linked to significantly reduced cancer pain and opioid dose (P<.001 for both>
  • QoL improved significantly (P=.018) after PCC.
  • Median survival period after PCC was 1.3 (interquartile range, 0.6-2.8) months.
  • 4% of patients had PCC-related AEs.

Limitations

  • A small number of patients.
  • Observational study.
  • Limited pain characterization.

Coauthored with Vijay Rathod, PhD